Skip to search formSkip to main contentSkip to account menu

olaparib

Known as: 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one 
A substance being studied in the treatment of breast, ovarian, and prostate cancers caused by mutations (changes) in the BRCA1 and BRCA2 genes. It is… 
National Institutes of Health

Related topics

Related topics

12 relations

Narrower (3)

AZD 2281LynparzaPARP Inhibitor AZD2281

Broader (4)

Antineoplastic AgentsPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase Inhibitors
NCIt Antineoplastic Agent TerminologyPARP1 protein, humanPoly(ADP-Ribose) Polymerase Inhibitors [MoA]olaparib 50 MG Oral Capsule

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.
6003Background: Combination cediranib (C) and olaparib (O) improved progression-free survival (PFS) in patients (pts) with… 
2019
2019
Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer.
5507 Background: The CLIO trial (NCT02822157) evaluated olaparib single-agent therapy versus standard of care chemotherapy in… 
Highly Cited
2016
Highly Cited
2016
Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer.
5500 Background: Olaparib (AZD2281; KU-0059436) is a novel, orally active PARP inhibitor that induces synthetic lethality in… 
2015
2015
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
2014
2014
Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin
Indoleamine 2,3-dioxygenase-1 (IDO) is an immunosuppressive molecule expressed by most human tumors. IDO levels correlate with… 
2013
2013
PARP inhibitors bounce back
A series of setbacks almost caused the demise of PARP inhibitors, but four companies are now beginning pivotal trials of these… 
2013
2013
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).
5505 Background: Previously, we reported that maintenance treatment with the oral PARP inhibitor olaparib (400 mg bid) led to a… 
Highly Cited
2012
Highly Cited
2012
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
Background:Olaparib (AZD2281) is a potent oral poly(ADP-ribose) polymerase inhibitor with anti-tumour activity and acceptable… 
Review
2011
Review
2011
PARP inhibitors--current status and the walk towards early breast cancer.
2011
2011
Targeting the missing links for cancer therapy
A continuing quest in clinical oncology is to effectively eliminate tumors without major side effects. But drugs rationally… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)